By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sunovion Pharmaceuticals Inc. 

84 Waterford Drive

Marlborough  Massachusetts  01752  U.S.A.
Phone: 508-481-6700 Fax:



Acadia  ACADIA has formed a broad CNS collaboration with Sepracor for the discovery and development of new drug candidates against muscarinic receptors.


Company News
Sunovion Announces Positive Results From Pivotal Study Evaluating Novel Drug Candidate Dasotraline In Children With ADHD 4/21/2017 11:27:20 AM
Sunovion To Present Data On Aptiom (Eslicarbazepine Acetate) At American Academy of Neurology 2017 Annual Meeting 4/19/2017 8:59:07 AM
Sunovion Announces Utibron Neohaler (Indacaterol/Glycopyrrolate) Inhalation Powder Now Available In The United States 4/3/2017 8:56:03 AM
Sunovion To Present Data On LATUDA (Lurasidone HCI) At The 25th European Congress Of Psychiatry 3/31/2017 6:18:43 AM
Sunovion Submits Supplemental New Drug Application To FDA For Use Of APTIOM (Eslicarbazepine Acetate) For The Treatment Of Partial-Onset Seizures In Children 4 Years Of Age And Older 3/13/2017 7:09:35 AM
Sunovion Announces Positive Topline Results From Study Evaluating Latuda (Lurasidone HCL) In Children And Adolescents With Bipolar Depression 2/27/2017 6:38:43 AM
Demi Lovato, Sunovion And Leading Advocacy Organizations Release Mental Health Documentary As Part Of Be Vocal Initiative 2/22/2017 6:19:14 AM
Sunovion’s Latuda (lurasidone HCl) Receives FDA Approval To Treat Adolescents With Schizophrenia 1/30/2017 9:53:02 AM
Sunovion Release: Biopharma Announces Pivotal Study Results For Novel Drug Candidate Dasotraline Demonstrating Significantly Improved Attention Deficit Hyperactivity Disorder Symptoms In Children Compared To Placebo 1/16/2017 7:05:58 AM
Sunovion Release: Massachusetts Biotech Touts Binge Eating and ADHD Mid-Stage Trials Data 1/13/2017 7:10:48 AM